01 September 2004
Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease
Maciej Świątkowski, Jacek Budzyński, Maria Kłopocka, Grzegorz Pulkowski, Karol Suppan, Jacek Fabisiak, Włodzimierz Morawski, Marcin MajerMed Sci Monit 2004; 10(9): CR524-529 :: ID: 11758
Abstract
Background:Juvenile nasopharyngeal angiofibroma (JNA)is a benign neoplasm, which represents less than 0,05%of all head and neck tumours. It affects almost solely adolescent males. Surgery is the main treatment modality. he purpose of this study was to present, based on 24 cases ,typical JNA features on CT and MRI.Material/Methods: We studied 34 patients with stable angina pectoris. In all subjects a medical history, a physical examination, and a stress test were performed at the beginning of the study and after two weeks of add-on rabeprazole therapy (20 mg b.i.d.).Results: Rabeprazole therapy significantly improved the outcome of the stress test in 27 patients (79%), prolonging mean stress exercise time (449±147 vs. 489±156s, p=0.027) and exercise time, leading to a maximum ST interval depression (360±167 vs. 467±148s, p=0.001), and also decreasing ST interval depression delta (1.9±1.1 vs. 1.5±0.9; p=0.013).Conclusions: In 79% of our study subjects, rabeprazole improved stress test results in CAD patients, which implies that at least some of their symptoms were related to GERD. A proton pump inhibitor exerted a favorable effect on the frequency of angina-like chest pain and the results of the treadmill stress test.
Keywords: Angina Pectoris - drug therapy, Benzimidazoles - therapeutic use, Coronary Arteriosclerosis - drug therapy, Gastric Acid - metabolism, Gastroesophageal Reflux - drug therapy, 2-Pyridinylmethylsulfinylbenzimidazoles, Angina Pectoris - drug therapy, Anti-Ulcer Agents - therapeutic use, Benzimidazoles - therapeutic use, Comorbidity, Coronary Artery Disease - physiopathology, Exercise Test, Gastric Acid - metabolism, Gastroesophageal Reflux - drug therapy, Omeprazole - therapeutic use, rabeprazole
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952